Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 311

1.

Ketamine anaesthesia interferes with the quinolinic acid-induced lesion in a rat model of Huntington's disease.

Jiang W, Büchele F, Papazoglou A, Döbrössy M, Nikkhah G.

J Neurosci Methods. 2009 May 15;179(2):219-23. doi: 10.1016/j.jneumeth.2009.01.033. Epub 2009 Feb 7.

PMID:
19428530
2.

Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid.

Harris CA, Miranda AF, Tanguay JJ, Boegman RJ, Beninger RJ, Jhamandas K.

Br J Pharmacol. 1998 May;124(2):391-9.

3.

Quinolinic acid-induced increases in calbindin D28k immunoreactivity in rat striatal neurons in vivo and in vitro mimic the pattern seen in Huntington's disease.

Huang Q, Zhou D, Sapp E, Aizawa H, Ge P, Bird ED, Vonsattel JP, DiFiglia M.

Neuroscience. 1995 Mar;65(2):397-407.

PMID:
7777157
4.
5.

Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease.

Wei H, Qin ZH, Senatorov VV, Wei W, Wang Y, Qian Y, Chuang DM.

Neuroscience. 2001;106(3):603-12.

PMID:
11591460
7.

Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum.

Popoli P, Pintor A, Domenici MR, Frank C, Tebano MT, Pèzzola A, Scarchilli L, Quarta D, Reggio R, Malchiodi-Albedi F, Falchi M, Massotti M.

J Neurosci. 2002 Mar 1;22(5):1967-75.

8.

[Behavior characterization of a model of Huntington's disease in rats, induced by quinolinic acid].

Francis L, Cruz R, Antúnez I, Rosillo JC.

Rev Neurol. 2000 Jun 1-15;30(11):1016-21. Spanish.

PMID:
10904945
9.

Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease.

Scattoni ML, Valanzano A, Pezzola A, March ZD, Fusco FR, Popoli P, Calamandrei G.

Behav Brain Res. 2007 Jan 25;176(2):216-21. Epub 2006 Nov 22.

PMID:
17123640
10.

Antioxidant treatment protects striatal neurons against excitotoxic insults.

Nakao N, Grasbon-Frodl EM, Widner H, Brundin P.

Neuroscience. 1996 Jul;73(1):185-200.

PMID:
8783241
11.

The 1993 Upjohn Award Lecture. Quinolinic acid induced brain neurotransmitter deficits: modulation by endogenous excitotoxin antagonists.

Jhamandas KH, Boegman RJ, Beninger RJ.

Can J Physiol Pharmacol. 1994 Dec;72(12):1473-82. Review.

PMID:
7736338
12.

Asymmetrical motor behavior in rats with unilateral striatal excitotoxic lesions as revealed by the elevated body swing test.

Borlongan CV, Randall TS, Cahill DW, Sanberg PR.

Brain Res. 1995 Apr 3;676(1):231-4.

PMID:
7796175
13.

Behavioral and anatomical effects of quinolinic acid in the striatum of the hemiparkinsonian rat.

Olds ME, Jacques DB, Kopyov O.

Synapse. 2005 Jan;55(1):26-36.

PMID:
15499610
14.

Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models.

Portera-Cailliau C, Hedreen JC, Price DL, Koliatsos VE.

J Neurosci. 1995 May;15(5 Pt 2):3775-87.

15.

Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease.

Shear DA, Dong J, Gundy CD, Haik-Creguer KL, Dunbar GL.

Prog Neuropsychopharmacol Biol Psychiatry. 1998 Oct;22(7):1217-40.

PMID:
9829299
16.

The role of group I and group II metabotropic glutamate receptors in modulation of striatal NMDA and quinolinic acid toxicity.

Orlando LR, Alsdorf SA, Penney JB Jr, Young AB.

Exp Neurol. 2001 Jan;167(1):196-204.

PMID:
11161608
18.

Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease.

Sapko MT, Guidetti P, Yu P, Tagle DA, Pellicciari R, Schwarcz R.

Exp Neurol. 2006 Jan;197(1):31-40. Epub 2005 Aug 15.

PMID:
16099455
19.

Normal sensitivity to excitotoxicity in a transgenic Huntington's disease rat.

Winkler C, Gil JM, Araújo IM, Riess O, Skripuletz T, von Hörsten S, Petersén A.

Brain Res Bull. 2006 Apr 14;69(3):306-10. Epub 2006 Jan 20.

PMID:
16564426
20.

Excitotoxic brain damage involves early peroxynitrite formation in a model of Huntington's disease in rats: protective role of iron porphyrinate 5,10,15,20-tetrakis (4-sulfonatophenyl)porphyrinate iron (III).

Pérez-De La Cruz V, González-Cortés C, Galván-Arzate S, Medina-Campos ON, Pérez-Severiano F, Ali SF, Pedraza-Chaverrí J, Santamaría A.

Neuroscience. 2005;135(2):463-74.

PMID:
16111817

Supplemental Content

Support Center